Changing the Course of Cancer Treatment
AdvanCell is a vertically integrated, clinical stage radiopharmaceutical company developing novel targeted alpha therapies to improve survival and the quality of life for patients with cancer
![](https://cdn.prod.website-files.com/64c9af957e453c8bae438e23/64cff740aea07df5b0f0b124_Image%20(4).webp)
829665046
Development Pipeline
AdvanCell is developing a portfolio of Targeted Alpha Therapies for the treatment of cancer including: prostate, skin, pancreatic, breast, bladder, colorectal, kidney, lung, and ovary.
![](https://cdn.prod.website-files.com/64c9af957e453c8bae438e23/6696569a0cbfeef5484c518f_Pipeline.png)
Groundbreaking Technology
![](https://cdn.prod.website-files.com/64c9af957e453c8bae438e23/64cff97162f87a6033ac53ef_Frame%204.webp)
THERAPIES
Proprietary ²¹²Pb production technology provides access to an unmatched supply of alpha isotopes to accelerate clinical development of a portfolio of targeted alpha therapies.
Read more
![](https://cdn.prod.website-files.com/64c9af957e453c8bae438e23/64cff94d2293c2299fce45c2_01_FRONT%203%20QUARTER%201%20(2).webp)
ALPHA 212 SUPPLY
Alpha 212 is the product of AdvanCell’s ²¹²Pb generator. It is a quality-controlled dose of ²¹²Pb as an Active Pharmaceutical Ingredient (API) manufactured to international GMP standards.
Read more